Indication
Obsessive-Compulsive Disorder
27 clinical trials
22 products
4 drugs
Product
TroriluzoleClinical trial
A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive DisorderStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive DisorderStatus: Recruiting, Estimated PCD: 2024-12-01
Product
PlaceboClinical trial
A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive DisorderStatus: Active (not recruiting), Estimated PCD: 2020-06-02
Clinical trial
A Multicenter, Long-Term Open-Label Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive DisorderStatus: , Estimated PCD: 2025-06-01
Clinical trial
PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)Status: Recruiting, Estimated PCD: 2024-06-30
Product
PsilocybinClinical trial
Effects of Ondansetron in Obsessive-compulsive and Tic DisordersStatus: Completed, Estimated PCD: 2022-05-16
Product
OndansetronClinical trial
MDMA-Assisted Cognitive Behavioral Therapy (CBT) Compared With Methamphetamine-Assisted CBT in Obsessive-Compulsive Disorder (OCD): A Phase II StudyStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Product
MethamphetamineClinical trial
Efficacy of Nitrous Oxide in OCD: Pilot StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Nitrous OxideProduct
NitrogenClinical trial
Ketamine Therapy in Obsessive-compulsive Disorder and Its Effects on Neuropsychological Function Under Stress in a Cross-over TrialStatus: Recruiting, Estimated PCD: 2026-01-01
Product
KetamineProduct
MidazolamClinical trial
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCDStatus: Recruiting, Estimated PCD: 2024-07-31
Product
FluoxetineClinical trial
A Precision Medicine Approach to OCD Treatment: Targeting NeuroinflammationStatus: Recruiting, Estimated PCD: 2024-04-01
Drug
CelecoxibClinical trial
Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot StudyStatus: Recruiting, Estimated PCD: 2025-04-01
Product
DextromethorphanClinical trial
A Clinical Trial to Evaluate the Safety and Tolerability of Fecal Microbiota Transplantation in a Population With Obsessive-compulsive DisorderStatus: Recruiting, Estimated PCD: 2024-03-01
Product
FMT + SIMBAClinical trial
An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept StudyStatus: Recruiting, Estimated PCD: 2024-09-01
Drug
cannabidiolClinical trial
Effect of Stepped Care in Internet-Based Cognitive Behavioral Therapy for Adults With Obsessive-Compulsive Disorder：A Three-Arm Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)Status: Recruiting, Estimated PCD: 2028-11-01
Drug
KetamineProduct
NaltrexoneClinical trial
Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCDStatus: Completed, Estimated PCD: 2023-04-30
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study of Tolcapone for OCDStatus: Recruiting, Estimated PCD: 2025-06-01
Product
TolcaponeDrug
VarlilumabClinical trial
NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCDStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2024-06-01
Clinical trial
Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS)Status: Recruiting, Estimated PCD: 2024-10-31
Product
NaproxenClinical trial
An Open-Label Study of Dronabinol, a Cannabinoid Agonist, for Obsessive Compulsive Disorder and the Obsessive-Compulsive Spectrum Disorders Trichotillomania and Pathological Skin PickingStatus: Completed, Estimated PCD: 2011-01-01
Product
DronabinolProduct
PropanololClinical trial
A Retrospective Chart Review of Patients Undergoing Ketamine Infusions at the Canadian Rapid Treatment Center of ExcellenceStatus: , Estimated PCD: 2023-12-01
Clinical trial
Effects of Psilocybin in Obsessive Compulsive DisorderStatus: Recruiting, Estimated PCD: 2025-09-12
Clinical trial
University of Iowa Interventional Psychiatry Service Patient RegistryStatus: Recruiting, Estimated PCD: 2050-08-01
Product
EsketamineClinical trial
Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive DisorderStatus: Withdrawn, Estimated PCD: 2024-05-08
Product
Nabilone